Vasomotor Symptoms Associated With Menopause

Women's Health
5
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Bayer
LYNKUETApproved
elinzanetant
Bayer
oral2025

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
3 programs
3
1
ElinzanetantPhase 31 trial
ElinzanetantPhase 31 trial
ElinzanetantPhase 31 trial
Active Trials
NCT05042362Completed396Est. Nov 2023
NCT05030584Completed628Est. Feb 2024
NCT05099159Completed400Est. Oct 2023
AbCellera
AbCelleraBC - Vancouver
1 program
1
ABCL635Phase 1/21 trial
Active Trials
NCT07118891Recruiting136Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BayerElinzanetant
BayerElinzanetant
BayerElinzanetant
AbCelleraABCL635

Clinical Trials (4)

Total enrollment: 1,560 patients across 4 trials

NCT05099159BayerElinzanetant

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

Start: Oct 2021Est. completion: Oct 2023400 patients
Phase 3Completed
NCT05042362BayerElinzanetant

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

Start: Aug 2021Est. completion: Nov 2023396 patients
Phase 3Completed
NCT05030584BayerElinzanetant

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

Start: Aug 2021Est. completion: Feb 2024628 patients
Phase 3Completed
NCT07118891AbCelleraABCL635

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

Start: Jun 2025Est. completion: Feb 2027136 patients
Phase 1/2Recruiting

Related Jobs in Women's Health

Senior Medical Science Liaison

Ferring Pharmaceuticals
Bangkok, Thailand
20h ago

Senior Key Account Manager

Ferring Pharmaceuticals
Bucureşti, Romania
1w ago

Territory Representative - Miami

Caldera Medical
Miami, FL, US
1w ago

Sales Representative Gynecological Health

Medtronic
Malaga, Andalucia, Spain
1w ago

Sales Representative, Women's Health - Charleston, SC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Sales Representative, Women's Health- Charlotte, NC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,560 patients
2 companies competing in this space

Related Indications

Endometriosis(43)Menopause(27)Polycystic Ovary Syndrome(14)Postmenopause(8)Controlled Ovarian Stimulation(5)Polycystic Ovarian Syndrome(3)Preeclampsia(3)Uterine Fibroids(3)Uterine Leiomyomata (Fibroids)(3)Ovarian Hyperstimulation Syndrome(3)